Metastatectomy prior to immunochemotherapy for metastatic renal cell carcinoma

Urologia Internationalis

Volumn 76, Issue 3, 2006, Pages 256-263

  Sang, Eun Lee ^a   Kwak, Cheol ^b   Byun, Seok Soo ^a   Myung, Chul Gill ^a   In, Ho Chang ^a   Yong, June Kim ^a   Sung, Kyu Hong ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

5 Fluorouracil; Interferon ; Interleukin 2; Metastatectomy; Metastatic renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; FLUOROURACIL; IMMUNOLOGIC AGENT; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DISEASE COURSE; DRUG FEVER; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY SURGERY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATECTOMY; MYALGIA; NAUSEA; PERFORMANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SKIN DISEASE; SURGICAL TECHNIQUE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 33645663035     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091630     Document Type: Review

References (29)

1. Van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH: Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer 2000;82: 772-776.
2. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jurgenson S, Wandert T, Patzelt T, Reitz M: IL-2 in combination with IFN-α and FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85: 1130-1136.
3. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HG: Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol 1996;156:18-21.
4. Joffe JK, Banks RE, Forbes MA, Hallam S, Jenkins A, Patel PM, Hall GD, Velikova G, Adams J, Crossley A, Johnson PW, Whicher JT, Selby PJ: A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 1996;77:638-649.
5. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993;29A(suppl 5):S6-S8.
6. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M: Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospective randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22:1188-1194.
7. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-1043.
8. Sengupta S, Leibovich BC, Blute ML, Zincke H: Surgery for metastatic renal cell cancer. World J Urol 2005;23:155-160.
9. Mickisch GH: Urologic approaches to metastatic renal cell carcinoma. Onkologie 2001;24: 122-126.
10. Freed SZ, Halperin JP, Gordon M: Idiopathic regression of metastases from renal cell carcinoma. J Urol 1977;118:538-542.
11. Marcus SG, Choyke PL, Reiter R, Jaffe GS, Alexander RB, Linehan WM, Rosenberg SA, Walther MM: Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993;150:463-466.
12. Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC: Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 1999;162:43-45.
13. Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB: Nephrectomy before interleukin-2 therapy for patients with metastatectomy renal cell carcinoma. J Urol 1997;158:1691-1695.
14. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: a randomized trial. Lancet 2001;358:966-970.
15. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Eng J Med 2001;345:1655-1659.
16. Wood CG: The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin N Am 2003;30:581-588.
17. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with advanced renal cell carcinoma. Cancer Res 1988;48:7310-7313.
18. Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, Oskam R, Franks CR: Prognostic factors for survival in advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3:475-480.
19. Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Perol D, Lasset C: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002;13:1460-1468.
20. Padrik P: Prognostic factors of immunotherapy in metastatic renal cell carcinoma. Med Oncol 2003;20:325-334.
21. Hofmann H, Neef H, Krohe K, Andreev P, Silber R: Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 2005;48:77-82.
22. Alves A, Adam R, Majno P, Delvart V, Azoulay D, Castaing D, Bismuth H: Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol 2003;10:705-710.
23. Lau WK, Zincke H, Lohse CM, Cheville JC, Weaver AL, Blute ML: Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review. BJU Int 2003;91:775-779.
24. Harada Y, Nonomura N, Kondo M, Nishimura K, Takahara S, Miki T, Okuyama A: Clinical study of brain metastasis of renal cell carcinoma. Eur Urol 1999;36:230-235.
25. van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM: Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 1999;35:197-203.
26. de Kernion JB, Ramming KP, Smith RB: The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978;120: 148-152.
27. O'Brien MF, Rea D, Rogers E, Bredin H, Butler M, Grainger R, McDermott TE, Mullins G, O'Brien A, Twomey A, Thornhill J: Interleukin-2, interferon-α and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience. Eur Urol 2004;45: 613-618.
28. Negrier S: Better survival with interleukin-2-based regimen? Possibly only in highly selected patients. J Clin Oncol 2004;22:1174-1176.
29. Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J: Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995;154:32-34.